About us
Our History
Company overview
Tianming Pharmaceutical, founded in 2010, is a leading innovator in R&D, production, and sales of new drugs, including antibiotics, cardiovascular, diabetes, anti-tumor, anti-aging, and antiviral products. Leveraging our scientific expertise and industry experience, we deliver top-quality pharmaceuticals for research and production.
Renowned for high-quality products, flexibility, and customer service, Tianming has global reach with production bases in China and sales companies in India and Bangladesh, partnering with manufacturers worldwide.
What We Offer
Our factory
Tianming R&D Center’s cutting-edge technology leads the development of new and improved drugs. In the filling workshop, precise operation and meticulous packaging ensure that every product reaches customers with the highest quality. Environmental protection is our compass. We practice green production, implement environmental measures, build a comprehensive safety system, and strive to minimize our carbon footprint.
Our powerful transportation network delivers products worldwide, ensuring seamless connection from raw materials to users, providing high-quality and reliable pharmaceutical solutions for global customers.
Our Vision and Values
Innovative drugs
Tianming Pharmaceuticals is committed to becoming a world-leading biopharmaceutical innovator, constantly breaking through scientific boundaries, and contributing to the cause of human health with outstanding R&D strength and innovative spirit.
With the vision of “making innovative drugs and realizing the dream of health”, while constantly pursuing innovative development, Tianming has successfully won more than 200 patents. It is not only a strong proof of our R&D strength, but also an important milestone for Tianming’s continued deep cultivation and breakthroughs in the field of biopharmaceuticals.
What's News
Latest news at Tianming
GLP-1 for Weight Loss: How These Drugs Work and What the Latest Data Shows
This article elucidates the mechanism of action of GLP-1, the clinical data—including real-world efficacy and side effects—of drugs approved as of 2025 and novel oral therapies, their applicable patient populations, and their impact on the pharmaceutical supply chain.
High-Purity Diabetes Drug Intermediates | SGLT2, GLP-1 & Orforglipron
It clarifies the core differences between SGLT2 inhibitors and GLP-1 receptor agonists, covering their mechanisms, clinical advantages and representative products. It highlights Orforglipron, a breakthrough oral small-molecule GLP-1 agonist.
Essential Documentation for Regulatory Submission of Intermediates (DMF/CEP)
Master regulatory submission for pharmaceutical intermediates with DMF/CEP documentation best practices. Fix common deficiencies, align with FDA/EDQM guidelines, and streamline review processes.